Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
67 results about "CD146" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
CD146 (cluster of differentiation 146) also known as the melanoma cell adhesion molecule (MCAM) or cell surface glycoprotein MUC18, is a 113kDa cell adhesion molecule currently used as a marker for endothelial cell lineage. In humans, the CD146 protein is encoded by the MCAM gene.
Isolation of pericytes
In one embodiment, the invention provides a pericyte having a marker pattern comprising CD146+, CD34−, and CD45−, wherein said pericyte is substantially isolated from cells that are CD146− or CD31+ or CD34+ or CD45+ or CD56+ or NG2− or CD133−. The invention also provides populations of such pericytes. In another embodiment, the invention provides a method for isolating a pericyte. In another embodiment, the invention provides a method for modeling tissue in vivo.
Owner:UNIVERSITY OF PITTSBURGH
Perivascular mesenchymal precursor cell induced blood vessel formation
Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as STRO-1 and CD146 / MUC18. The perivascular mesenchymal precursor cell is shown to induce neovascularisation and improvement in cardiac function. Suitable administration of preparations of the mesenchymal precursor cells are useful for treatment of cardiovascular diseases, cerebrovascular diseases and peripheral vascular diseases.
Owner:MESOBLAST
Immunoconjugates with improved efficacy for the treatment of diseases
InactiveUS20070196274A1Improve therapeutic efficacyHigh detection sensitivityIn-vivo radioactive preparationsImmunoglobulins against animals/humansAntibody conjugateCD11a
The invention provides therapeutic or diagnostic antibodies with modified N— or C-terminal sequences that are enriched with lysine or tyrosine residues. These lysine or tyfosine residues can be used to couple radioisotopes, cytotoxic agents, or detectable labels. The increased stoichiometric ratios of these agents in the antibody conjugates lead to improved therapeutic efficacy or enhanced detection sensitivity. Non-limiting examples of antibodies suitable for the present invention include anti-CD22, anti-ErbB2, anti-VEGF, anti-EGFR, anti-VEGFR, anti-Her-3, anti-Her-4, anti-CEA, anti-CTLA-4, anti-CD4, anti-CD3, anti-CD20, anti-TNF-a, anti-CD11a, anti-Lewis Y antigen, anti-TrailR, anti-IL2R, anti-CD30, anti-CD146, anti-CD147, anti-alpha V integrin beta, anti-CD19, anti-GD2, anti-3H11, anti-EBV, anti-HIV, anti-HBV, anti-HCV, and other disease-specific antibodies.
Owner:WELSON PHARMA
Antihuman CD146 monoclone antibody, composition containing the same, and method for testing dissolubility CD146
ActiveCN101245101AHigh sensitivityCell receptors/surface-antigens/surface-determinantsImmunoglobulins against cell receptors/antigens/surface-determinantsSolubilityDisease
The invention relates to a group of anti-human CD146 molecules which are developed by utilizing the biological technology and an established high-sensitive sandwich ELISA method for detecting the solubility CD146. The invention includes anti-human CD146 mouse monoclonal antibodies of AA1, AA2, AA3, AA4, AA5 and AA7, and the method of utilizing the combination of the antibodies and the sandwich ELISA specificity for detecting the solubility CD146. The group of antibodies can identify the human source CD146 on the molecular, the cellular and the tissue levels, which can be divided into two categories based on the identified different epitopes. The sandwich ELISA method which is combined by the antibody AA1 and another strain of anti-human CD146 mouse monoclonal antibody AA98 can detect the solubility CD146 at each milliliter nano-gram level. The antibodies and the detection means can become the effective detection or diagnosis tools and method in the basic research or the clinical application and provide good carriers for the targeted therapy of the CD146-related diseases at the same time.
Owner:INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
Root canal filler and dental tissue regeneration method
ActiveUS20110020310A1Improve regenerative abilityIncrease differentiationBiocideDigestive systemPulpectomyCell-Extracellular Matrix
Provided is a novel and creative dental tissue regeneration method for regenerating dental tissue after pulpectomy or the enlargement and cleaning of an infected root canal. After pulpectomy or the enlargement and cleaning of an infected root canal, a root canal filler (200) having an extracellular matrix (210) containing the cells (220) enriched for dental pulp stem cells, is inserted into the apical side of the root canal of a target tooth (100). The cells including dental pulp stem cells include at least one of the following: dental pulp SP cells, CD31-negative and CD146-negative cells, CD24-positive cells, CD105-positive cells, and CD150-positive cells. For instance, dental pulp SP cells are CD31− and CD146− negative. Even if pulpitis due to deep caries occurs, appropriate dental pulp regeneration and recovery of dental pulp function are possible.
Owner:NAT CENT FOR GERIATRICS & GERONTOLOGY
Identifying circulating tumor cells (CTCS) using cd146 in breast cancer patients
InactiveUS20120178645A1Increased riskPoor prognosisMicrobiological testing/measurementLibrary screeningCirculating cancer cellBiology
The present invention relates to a method for diagnosing cancer in a subject said method comprising the steps of providing a biological sample from a subject, and determining the expression of the MCAM gene in a circulating tumor cell (CTC) in said biological sample.
Owner:ERASMUS UNIV MEDICAL CENT ROTTERDAM ERASMUS MC
Anti-human CD146 monoclonal antibodies, compositions containing anti-human CD146 monoclonal antibodies, and soluble CD146 detection method
The present invention relates to a group of anti-human CD146 molecules developed by using a biological technology and an established high sensitivity sandwich ELISA method for soluble CD146 detection. The present invention provides anti-human CD146 mouse monoclonal antibodies (AA1, AA2, AA3, AA4, AA5 and AA7), and a method for specially detecting soluble CD146 by using antibody combinations and sandwich ELISA, wherein the antibodies can specifically recognize human source CD146 at a molecular level, a cellular level and a tissue level, and can be divided into two classes based on recognition of different epitopes. With an antibody AA1 and anti-human CD146 mouse monoclonal antibody AA98 combined sandwich ELISA method, nanogram-scale soluble CD146 in per ml of the solution can be detected. The antibodies and the detection method can become effective detection or diagnosis tools and methods in basic researches or clinical applications, and can further provide good carriers for targeted therapies of CD146-related diseases.
Owner:INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
Method of distinguishing mesenchymal stem cells and method of determining purity of mesenchymal stem cells
InactiveUS20180059109A1High purityMicrobiological testing/measurementBiological material analysisFibroblastMesenchymal stem cell
A method of distinguishing mesenchymal stem cells (MSCs) from fibroblasts is provided. Also provided is a method of increasing a purity of mesenchymal stem cells (MSCs) population in a cell culture. The above-mentioned methods each comprise a step of sorting or isolating the cells by a marker of CD146 from a cell culture derived from a placenta-related tissue. Further provided is a method of assessing purity of mesenchymal stem cells (MSCs) in a cell culture derived from a placenta-related tissue, comprising determining the percentage of cells expressing CD146 in the culture.
Owner:MERIDIGEN BIOTECH
Isolated multipotent mesenchymal stem cell from human adult glomeruli (hgl-msc), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney
ActiveUS20110256111A1Inhibits PHA-induced PBMC proliferationBiocideArtificial cell constructsZona glomerulosaDisease
The invention relates to an isolated multipotent glomerular mesenchymal stem cell derived from adult human kidney (hGL-MSC), which is characterised by the marker profile CD133−, CD146+, CD34− and CD105+. A method of preparing the hGL-MSC of the invention form decapsulated glomeruli is also disclosed, as well as the uses of the hGL-MSC of the invention in the regenerative treatment of the kidney, particularly for the treatment of injuries or diseases affecting renal glomeruli.
Owner:FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
Application of CD146 monoclonal antibody in detection and separation and identification of glioma perivascular cells
ActiveCN106589124AConforms to the characteristics of the structural hierarchyAccurate identificationCell dissociation methodsImmunoglobulins against cell receptors/antigens/surface-determinantsTumor vesselCell strain
An application of a CD146 monoclonal antibody in detection and separation and identification of glioma perivascular cells. The CD146 monoclonal antibody is prepared from a hybridoma cell strain which is assigned the accession number of CCTCC No: C2016183. The CD146 monoclonal antibody 4F10 has excellent specificity and can accurately recognize tumor perivascular cells. In addition, the CD146 monoclonal antibody 4F10 can be used for flow cytometry sorting and detection of glioma-derived pericytes.
Owner:THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV
Detection method of molecules, and appliction
InactiveCN1916632AReduce dosageHigh sensitivityMaterial analysis by optical meansSystemic vasculitisWhite blood cell
A method for detecting CD146 molecule includes utilizing protein chip and optical oval polarization microscope imaging technique to prepare CD146 antibody optical chip being used to detect CD146 content in body liquid of patient, utilizing stream cell technique to detect CD146 presentation state on white blood cell of patient.
Owner:INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
Enrichment and identification of fetal cells in maternal blood and ligands for such use
ActiveCN103261439AMicrobiological testing/measurementBiological material analysisHybridization probeHematological test
The present invention relates to enrichment and / or identification of fetal cells of a maternal blood sample using fetal cell specific ligands and / or fetal cell specific hybridization probes wherein the ligand or probes are directed to an endothelial / mesenchymal marker, e.g. CD105, CD146 or CD141, in a first round of enrichment and the ligand or probes, in a second round of enrichment, are directed to an epithelial marker, e.g. a cytokeratin, such as CK7, CK8, CK18 or CK19. Enriched or identified fetal cells may be subjected to steps of detection or diagnosis, wherefore the present invention enables non- invasive 5 prenatal diagnostics.
Owner:アルセディバイオテックエーピーエス
Thermosensitive polymer vesicle and preparation method and application thereof
ActiveCN109620965APromote proliferation and differentiationEasy to rebuildDigestive systemPharmaceutical non-active ingredientsBiotin-streptavidin complexPeriodontal ligament stem cells
The invention relates to a thermosensitive polymer vesicle and a preparation method and an application thereof. The thermosensitive polymer vesicle includes a vesicle body assembled by amphiphilic thermosensitive block-containing polymers, and a biotin-modified Biotin-CD146 monoclonal antibody and streptavidin (SA) targeting to periodontal ligament stem cells (PDLSCs) and combined on the vesicle body. The thermosensitive polymer vesicle can be used as a hydrogen sulfide vector for application. Compared with the prior art, the thermosensitive polymer vesicle has the PDLSCs targeting property, can improve the proliferation and differentiation ability of the PDLSCs, promotes periodontal tissue remodeling under an inflammation environment, improves the orthodontic curative effect and safety inan inflammation state, and provides technical support for clinical application of gas molecules.
Owner:TONGJI UNIV
Compound containing cell targeting antibodies and Poly(I:C), preparation method and applications thereof
ActiveCN107693789AValid importPromote productionOrganic active ingredientsAntipyreticFc(alpha) receptorInterferon alpha
The present invention provides a compound CaP / PEI / poly(I:C) / SiO2-S-Ab containing cell targeting antibodies and Poly(I:C), wherein the compound uses calcium phosphate nanoparticles as the core, the surface of the core is grafted with PEI, the Poly(I:C) is adsorbed and loaded on the surface of the core, the outer portion of the core is a silica shell, and the silica shell is linked to four differentcell targeting antibodies (such as CD146 antibody targeting liver sinusoidal endothelial cells, F4 / 80 antibody targeting kupffer cells, IgG1 isotype control antibody targeting IgG1 antibody expression Fc receptor cells, and IgG2 isotype control antibody targeting IgG2 antibody expression Fc receptor cells). The invention further provides a preparation method and medical uses of the compound. According to the present invention, with the compound, the poly(I:C) can reach the intrahepatic cells in the targeted manner so as to bind the poly(I:C) to TLR3, such that the generation of interferons and proinflammatory cytokines can be enhanced by activating different immune cell TLR3-mediated signaling pathways so as to provide the anti-HBV virus effect.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV
Stem cells expressing mesenchymal and neuronal markers, compositions thereof, and methods of preparation thereof
The invention provides a method of producing human immature dental pulp stem cells (hIDPSCs) expressing CD44 and CD13 and lacking expression of CD146. The invention also provides compositions for usein the treatment of a neurological disease or condition selected from the group consisting of Parkinson's disease (PD), multiple sclerosis, 5 amyotrophic lateral sclerosis (ALS), stroke, autoimmune encephalomyelitis, diabetic neuropathy, glaucomatous neuropathy, Alzheimer's disease, Huntington's disease (HD), autism, schizophrenia, stroke, ischemia, a motor disorder, and a convulsive disorder.
Owner:AVITA INT +1
CD146 and antibody diagnosis thereof, and application in treating triple negative breast cancer
The invention relates to CD146 and antibody diagnosis thereof, and an application thereof in treating triple negative breast cancers. For a first time, the invention provides that CD146 is a novel target of triple negative breast cancer, and an anti-CD146 antibody might become a novel targeting medicine for treating the disease. Therefore, the invention provides an application of CD146 or anti-CD146 antibody or a functional form of the antibody in preparing medicines used for diagnosing and / or treating triple negative breast cancers. CD146 molecules are subjected to specific high expression in triple negative breast cancer tissues, and induce the occurrences of transformation of epithelial cell to mesenchymal cell in tumor cells. Therefore, tumor invasion migration is promoted. Therefore, the mechanism for CD146 antibody to treat triple negative breast cancer is mainly that the CD146 antibody inhibits the mesenchymal cell characteristics of triple negative breast cancer, and reduces the metastasis invasion capacity thereof. Compared with common chemotherapy medicines, the anti-CD146 antibody has the advantages of low side effects and clear target. The anti-CD146 antibody does not cause whole-body side effect.
Owner:INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
A kit, a system and a method for determining patient marrow microenvironment after hematopoietic stem cell transplantation
ActiveCN103743906AQuick evaluationAccurate evaluationIndividual particle analysisFluorescence/phosphorescenceFluorescenceHematopoietic stem cell transplantation
The invention discloses a kit, a system and a method for determining patient marrow microenvironment after hematopoietic stem cell transplantation, wherein the applications of the kit, the system and the method are based on a flow cytometer, and the following fluorescently-labeled monoclonal antibody reagents are arranged in the kit: CD34-FITC, CD146-PE, CD45-PerCP and CD133-APC. The system comprises a main control computer unit, and a storage unit for storing empirical data and diagram, and the configuration of the hardware is an important guarantee for implementing determination. An expression proportion of a CD45-CD34-CD146+ cell in a bone marrow mononuclear cell is firstly used as an index for evaluating the quality of the marrow microenvironment of a blood disease patient after hematopoietic stem cell transplantation, has guiding significance for predicting generation of transplantation badness of the blood disease patient after hematopoietic stem cell transplantation, and has important reference value for guidance of making a clinic treatment scheme for a transplantation badness patient.
Owner:SHANGHAI TISSUEBANK MEDICAL LAB CO LTD
Kit for verifying endodontium mesenchymal stem cells
ActiveCN105866432AImprove the efficiency of induced differentiationShorten the time to induce differentiationCulture processSkeletal/connective tissue cellsSurface markerAdipogenesis
The invention discloses a kit for verifying endodontium mesenchymal stem cells. The kit comprises a flow phenotype detection reagent set, cell fixation liquid, an ordinary culture medium, an adipogenesis induction and detection reagent set, an osteogenesis induction and detection reagent set and a chondrogenesis induction and detection reagent set. Usually, conventional osteogenesis induction and adipogenesis induction need about 24 days, consumed time is long, and induction efficiency is low; by the kit, the time for osteogenesis induction and adipogenesis induction is shortened to 18 days, induction efficiency is improved, and induction time is shortened; conventional flow detection mainly aims at universal surface markers of mesenchymal stem cells, but the endodontium mesenchymal stem cells have positively-expressed surface markers CD146 which are different from the surface markers of other mesenchymal stem cells; CD146 antibodies are added into the kit, and accordingly, accurate verification results can be acquired.
Owner:天津欣普赛尔生物医药科技有限公司
Human endometriosis cell
The present invention discloses a human endometriosis cell, EM 257, which has been stored in the food industry research and development institute. Results obtained from a flow cytometry reveal that the human endometriosis cell of the present invention is positive for the mesnchymal stem cell surface antigens, such as CD44, CD73, CD105 and CD146. In different differentiation conditions, the human endometriosis cell of the present invention can be differentiated into osteogenic or adipogenic lineage cells.
Owner:NATIONAL CHANGHUA UNIVERSITY OF EDUCATION
Pharmaceutical composition for the prevention or treatment of a pulmonary disorder comprising mesenchymal stem cells having improved proliferation and differentiation capacity
ActiveUS20170360839A1Improved differentiation capacityIncreased proliferationSkeletal/connective tissue cellsUnknown materialsDiseaseCell marker
A pharmaceutical composition for the prevention or treatment of a pulmonary disorder is provided. The composition contains mesenchymal stem cells showing improved proliferation and differentiation capacity which are characterized by the expression or non-expression of one or more particular cell markers. Also, provided is a method for obtaining mesenchymal stem cells showing improved proliferation and differentiation capacity based on the expression or non-expression of such cell markers. The mesenchymal stem cells having improved proliferation and differentiation capacity can be easily obtained from mesenchymal stem cells of various origins based on the expression or non-expression of CD26, CD49f, CD146 and EGFR. The mesenchymal stem cells thus obtained can be effectively used for the prevention or treatment of a pulmonary disorder such as, for example, pulmonary emphysema.
Owner:MEDIPOST
Targeting breast cancer therapy based on stromal subtypes and cd146 composition
ActiveUS20170269088A1Facilitated DiffusionOrganic active ingredientsMicrobiological testing/measurementFhit geneWilms' tumor
Methods for targeted breast cancer therapy in a subject based upon evaluating the stromal subtypes and CD146 composition in the adjacent tissue. ER+ breast cancers contain two CAF subtypes defined by CD146 expression. CD146neg CAFs suppress ER expression in ER+ breast cancer cells, decrease tumor cell sensitivity to estrogen, switch ER proliferation dependency toward EGFR dependency and decrease tumor cell sensitivity to antiendocrine therapy. Conversely, the presence of CD146Ppos CAFs enhances ER expression in ER+ breast cancer cells and sustains ER-dependent proliferation and sensitivity to tamoxifen. Co-cultures of CD146pos CAFs with tamoxifen-resistant breast cancer cells restores sensitivity to tamoxifen. Gene expression profiles of patient breast tumors with predominantly CD146neg CAFs correlate with inferior clinical response to tamoxifen and worse patient outcomes. CAF composition contributes to treatment response and patient outcomes in ER+ breast cancer, and provide a target for drug development.
Owner:UNIV OF COLORADO THE REGENTS OF
Reagent for blocking interaction between Netrin-1 and CD146 and tumor treatment application thereof
The invention discloses an application of a reagent for blocking interaction between Netrin-1 and CD146 in preparing medicaments for inhibiting neovascularization and an application of the reagent in preparing medicaments for treating tumors, as well as a method for inhibiting neovascularization and treating tumors by blocking interaction between Netrin-1 and CD146.
Owner:INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
Application of CD146 as treatment target point to preparation of medicines for treating asthma airway remodeling
ActiveCN111228500AMicrobiological testing/measurementAntibody ingredientsAntiendomysial antibodiesAntagonism
The invention discloses an application of CD146 as a treatment target point to preparation of medicines for treating asthma airway remodeling, an application of the CD146 as the treatment target pointto screening and treating asthma, an application of substances for restraining CD146 expression or antagonism CD146 to preparation of medicines for treating bronchial asthma, and preferably, an application of preparation of medicines for asthma airway remodeling. The invention discloses an application of the CD146 for detecting plasma of patients suffering from bronchitis. For the first time, theinventor finds expression differences of the CD146 in serum of patients suffering from asthma and serum of normal people. The indexes can be used as a serum molecule marker for the bronchial asthma.The research indicates that HDM can worsen the airway remodeling through the CD146. Therefore, the CD146 can be used as the treatment target point to be used for screening and treating bronchial asthma. In accordance with an antibody of the CD146, the CD146 is also a treatment strategy for the bronchial asthma.
Owner:JIANGSU PROVINCE HOSPITAL THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIV
Application of CD146 + mesenchymal stem cell subpopulation in preparation of medicine for preventing and treating premature ovarian failure
PendingCN114366758AGood immune regulationPrevent proliferationUnknown materialsImmunological disordersOncologyT cell
The invention provides application of a CD146 + mesenchymal stem cell subset in preparation of a medicine for preventing and treating premature ovarian failure, and belongs to the technical field of biological medicines. The invention provides an application of a CD146 + mesenchymal stem cell subset in preparation of a medicine for preventing and treating premature ovarian failure. The treatment efficiency of the CD146 + MSCs and the treatment efficiency of the CD146-MSCs on a mouse POF model are compared, compared with a model group, the MSCs remarkably improve the premature ovarian failure, and the CD146 + subgroup has a slightly good trend compared with the CD146-MSCs. Meanwhile, the invention also provides an application of the CD146 + mesenchymal stem cell subset in preparation of a medicine for improving the immunoregulation ability of a premature ovarian failure patient. Experiments show that the CD146 + mesenchymal stem cell subgroup can significantly reduce the expression level of chemotactic factors and inflammatory genes and inhibit T cell proliferation, which indicates that the CD146 + subgroup has better immunoregulation ability.
Owner:北京三有利康细胞科技有限公司
A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
PendingCN113347991AMammal material medical ingredientsImmunological disordersCD33Natural Killer Cell Inhibitory Receptors
Owner:ミルテニイビオテックベーファーウントコーカーゲー
Application of soluble CD146 as blood-brain barrier injury marker in central nervous system diseases
ActiveCN110967489AIncreased sensitivityHigh sensitivityChemiluminescene/bioluminescenceBiological testingDiagnostic agentDifferential diagnosis
The invention relates to application of soluble CD146 protein in cerebrospinal fluid to preparation of a kit or a diagnostic agent for differential diagnosis, course judgment and / or medication guidance of individual inflammatory central nervous system diseases and the prepared kit or diagnostic agent. The application and the kit or the diagnostic agent have good sensitivity, accuracy, stability and operability.
Owner:INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
A fully-closed pipeline protein purification system and its application in the preparation of sterile pyrogen-free protein drugs
InactiveCN103159824BImmunoglobulins against cell receptors/antigens/surface-determinantsPeptide preparation methodsFree proteinMonoclonal antibody
Owner:INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
Tumor perivascular cell as well as separation method and application thereof
The invention discloses a tumor perivascular cell as well as a separation method and application thereof, and belongs to the technical field of biology. The method provided by the invention comprises the steps: stripping a fresh solid tumor tissue sample to obtain tumor blood vessels, cutting the tumor blood vessels into annular segments, then putting the tumor blood vessels of the annular segments into a pore plate pre-paved with matrigel, culturing by using a perivascular cell culture medium, and finally recovering the tumor perivascular cells from the matrigel. The tumor perivascular cells provided by the invention highly express four positive molecular markers of FAP[alpha], NG2, PDGFR[beta] and CD146, and do not express two negative molecular markers of CD31 and MYH11. By utilizing the tumor perivascular cells, a breakthrough of zero construction of an immortalized human colorectal cancer perivascular cell model is realized. The invention can provide an original material with reliable source, sufficient quantity and stable quality for researching biological functions and drug targets of solid tumor perivascular cells, and has a wide application prospect.
Owner:JINAN UNIVERSITY
Method of screening medicine for inhibiting or promoting new angiopoiesis
InactiveCN1162705CPrevent proliferationInhibit migrationMicrobiological testing/measurementBiological testingNeo angiogenesisDisease cause
Owner:INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
Application of CD146 and its antibody in diagnosis and treatment of triple negative breast cancer
Owner:INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com